Albert Sabin and prove its extraordinary effectiveness and safety. The Sabin vaccine worked in the intestines to block the poliovirus from entering the bloodstream. In the intestines, Sabin had discovered, the poliovirus multiplied and attacked. Thus, the oral vaccine broke the chain of transmission of the virus and allowed for the possibility that polio might one day be eradicated. Between 1955 and 1961, the oral vaccine was tested on at least 100 million people in the USSR, parts of Eastern Europe, Singapore, Mexico, and the Netherlands. The first industrial production and mass use of oral poliovirus vaccine (OPV) from Sabin strains was
Sabin Vaccine Institute Development, the Global Network for Neglected Tropical Diseases, and Vaccine Advocacy and Education. Through its Product Development Partnership (PDP), Sabin has worked with organizations such as King Saud University, Texas Children's Hospital Center, International Vaccine Institute, and George Washington University School of Medicine & Health Sciences toward its goals, with funding and support from the Bill & Melinda Gates Foundation, the National Institute of Allergy and Infectious Diseases, the Dutch Ministry of Foreign Affairs, the Brazilian Ministry of Health and other benefactors. In 2012, Sabin partnered with International Vaccine Institute to combine their research, development, and promotion efforts in Asia,